Bowel cancer "melted away" after immunotherapy, then stayed away

In the NEOPRISM-CRC trial, 32 patients with stage two or three bowel cancer of a specific genetic form received pembrolizumab for up to nine weeks before surgery instead of usual post-surgery chemotherapy. After nearly three years of follow-up, none had experienced recurrence, including those with small traces of disease remaining.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.